| Summary: | Background: Nasopharyngeal carcinoma (NPC) is one of those
cancers whose incidence and mortality rate are still high in
Indonesia. The standard therapy for NPC is a chemotherapy
that is given concurrently with radiotherapy (concurrent
chemoradiotherapy). However, not all patients receive
concurrent chemoradiotherapy because of other factors such
as its availability and patient's type of insurance. These
patients will undergo a different type of therapy, an
adjuvant chemotherapy or a neoadjuvant chemotherapy or other,
which are not the standard therapy.
Objective: To determine the 3-years survival rate of
patients with NPC that acquired any therapy other than CCRT
in RSUP Dr. Sardjito, Yogyakarta.
Method: A descriptive-analytical study using Kaplan-Meier
survival analysis to the 3-years survival of NPC patients
who did not undergo CCRT. Samples are obtained from January
2008 to December 2010, where 64 NPC patients met the
inclusion and exclusion criteria.
Result: The 3-years survival rate of NPC patients who
acquired any other therapy than CCRT is 32,8% with a mean
survival of 21 months altogether.
|
|---|